1stOncology™: Cancer Intelligence Service – Page 6780 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Calidi Biotherapeutics to Present Pre-Clinical SuperNova1 (SNV1) Data at the 2022 SITC Annual Meeting

On October 12, 2022 Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, reported a poster presentation highlighting pre-clinical data from the company’s SuperNova1 (SNV1) program at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, taking place in Boston, Massachusetts and virtually, November 8-12, 2022 (Press release, Calidi Biotherapeutics, OCT 12, 2022, View Source [SID1234621970]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Details of the poster presentation are below:

Title: SuperNova1 (SNV1), a novel oncolytic-cell based platform for cancer therapy
Abstract ID: 1137
Location: Poster Hall C
Date: November 10, 2022, 9:00 a.m. – 9:00 p.m. ET
Presenters: Duong H. Nguyen, Ph.D., Director of Translational Research and Innovation, and Antonio F. Santidrian, Ph.D., Senior Vice President, Global Head of Research and Development

Scorpion Therapeutics to Present Preclinical Proof-of-Concept Data for Highly Selective, Next-Generation Exon 20 Mutant EGFR Inhibitor at 34th EORTC-NCI-AACR Symposium

On October 12, 2022 Scorpion Therapeutics, Inc. ("Scorpion"), a pioneering oncology company redefining the frontier of precision medicine, reported that it will present preclinical proof-of-concept data for STX-721 in a poster session at the European Organisation for Research and Treatment of Cancer, the National Cancer Institute, and the American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("EORTC-NCI-AACR") Symposium 2022 in Barcelona, Spain, taking place October 26 – 28, 2022 (Press release, Scorpion Therapeutics, OCT 12, 2022, View Source [SID1234621969]).

STX-721 (formerly ST-5924) is Scorpion’s next-generation, orally delivered, small molecule designed with potential best-in-class selectivity for exon 20 insertion mutations in epidermal growth factor receptors ("EGFR"), a well-known, clinically validated oncogenic driver in non-small cell lung cancer ("NSCLC"). STX-721 is progressing through preclinical studies and Scorpion expects to submit an IND application to the U.S. Food and Drug Administration in 2023.

"We are excited to share foundational proof-of-concept data for STX-721, our next-generation EGFR inhibitor, which supports its potentially best-in-class product profile," said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion Therapeutics. "The Scorpion team developed this small molecule with the goal of delivering superior selectivity, as well as improved safety, tolerability and efficacy compared to currently marketed EGFR Exon 20 therapies and other drug candidates in development. We believe STX-721 could meaningfully improve the treatment of people living with EGFR exon 20-mutant NSCLC and look forward to advancing into clinical studies next year."

Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium

On October 12, 2022 Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, reported that the company will be presenting a poster on the mechanism of action of CYT-0851 at the 34th Annual EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium at the poster session "Molecular Targeted Agents 1" on Wednesday, October 26, 2022 (Abstract No. 71) (Press release, Cyteir Therapeutics, OCT 12, 2022, View Source [SID1234621968]). Cyteir shared preliminary evidence that CYT-0851 targeted monocarboxylate transporter (MCT) activity at an R&D Day in April 2022 and will provide additional mechanistic data on CYT-0851 at this symposium poster presentation.

"Elucidation of the mechanism of action of CYT-0851 as an inhibitor of monocarboxylate transporter activity has been an important accomplishment for the Cyteir Research team," said Paul Secrist, PhD, Chief Scientific Officer of Cyteir. "By impairing monocarboxylate transporter-mediated lactate transport, CYT-0851 disrupts glycolysis, a key metabolic pathway shared broadly by cancer cells. This knowledge has allowed the team to sharpen its focus on identifying biomarkers to select the patients most likely to benefit from CYT-0851 treatment."

"I am very proud of the Cyteir Research team for the speed with which they were able to pivot from a phenotypic screen to an understanding of the molecular target of CYT-0851, complementing our fast to the clinic development approach," said Markus Renschler, MD, President and Chief Executive Officer of Cyteir. "These research findings may provide additional insights on the patient population who could benefit from CYT-0851 therapy."

CYT-0851 is in a Phase 1/2 clinical trial as both a monotherapy and in combination with standard of care chemotherapy and has the potential to be a first-in-class MCT inhibitor. Translational analysis of patient samples is ongoing to confirm pharmacodynamic effects and to identify potential patient selection biomarkers. The April 2022 R&D Day can be accessed on demand in the Investor & Media section of the Cyteir website.

Palleon Pharmaceuticals to Present at the Oppenheimer Healthcare Private Company Showcase

On October 12, 2022 Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, reported that the company will present at the Oppenheimer Healthcare Private Company Showcase: The Next Wave on Tuesday, October 18, 2022 (Press release, Palleon Pharmaceuticals, OCT 12, 2022, View Source [SID1234621967]). Jim Broderick, M.D., Chief Executive Officer and founder of Palleon, will present a company overview at 11:45am PT and Palleon will host 1×1 investor meetings, which can be requested through Oppenheimer.

Triumvira Immunologics to Participate in Four Upcoming Healthcare Investor Conferences in October and November 2022

On October 12, 2022 Triumvira Immunologics ("Triumvira"), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, reported that Senior Management will participate in four upcoming healthcare investor conferences (Press release, Triumvira Immunologics, OCT 12, 2022, View Source [SID1234621966]).

Oppenheimer Private Company Showcase: The Next Wave: presentation at 2:35 pm PT on Tuesday, October 18th and available for investor meetings
Bank of America Healthcare Life Sciences Private Company Conference: available for in-person investor meetings on Thursday, October 20th
Wells Fargo Private Biotech Symposium: available for virtual investor meetings on Wednesday, November 2nd
Stifel 2022 Healthcare Conference: presentation on Wednesday, November 16th at 9:10 am ET and available for investor meetings